Marth, C. “Olaparib Shows Significant Progression-Free Survival Benefit in Phase III SOLO2 Trial:  ”. Cancer Breaking News, vol. 5, no. 2, Aug. 2017, pp. 3-4, doi:10.19156/cbn.2017.0041.